Date |
Title |
Feb 10, 2026
| ILiAD Biotechnologies Announces $115M Oversubscribed Series B Financing to Advance BPZE1 Pertussis Vaccine
|
Dec 2, 2025
| ILiAD Biotechnologies Announces Lancet Microbe Publication of BPZE1 Phase 2b Clinical Results in Human Challenge Model
|
Jan 27, 2025
| ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting
|
Dec 23, 2024
| ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay
|
Dec 4, 2024
| UK MHRA Grants Innovation Passport Designation to ILiAD Biotechnologies BPZE1 Next Generation Intranasal Pertussis Vaccine
|
Oct 1, 2024
| ILiAD Biotechnologies to Participate in Upcoming Investor Conferences
|
Aug 5, 2024
| Fierce Biotech Names ILiAD Biotechnologies to its 2024 Fierce 15
|
Jun 24, 2024
| ILiAD Biotechnologies Announces Planned Collaboration with Emmes Group, a New Mountain Capital Portfolio Company, to Conduct Upcoming Phase III Clinical Trials of BPZE1, the Leading Next-Generation Pertussis Vaccine
|
May 28, 2024
| ILiAD Biotechnologies Reports Positive Topline Interim Results from Phase 2b School-Age Trial of BPZE1 Pertussis Vaccine
|
Oct 18, 2023
| ILiAD Biotechnologies Announces Presentation at the 2023 World Vaccine Congress in Barcelona
|
Sept 5, 2023
| ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine
|
Apr 5, 2023
| ILiAD Biotechnologies Announces Presentation at the World Vaccine Congress
|
Mar 10, 2023
| ILiAD Biotechnologies Announces Publication of BPZE1 Adult Phase 2b Clinical Results in The Lancet
|
Sep 6, 2022
| ILiAD Biotechnologies Announces $42.8M Financing Round to Advance BPZE1 Pertussis Vaccine
|
Jun 27, 2022
| ILiAD Biotechnologies Announces Presentation of Additional Positive Data for its Next Generation Pertussis Vaccine at the 13th International Bordetella Symposium
|
Apr 26, 2022
| ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform
|
Jan 3, 2022
| FDA Grants ILiAD Biotechnologies Fast Track Designation for Next Generation Pertussis Vaccine BPZE1
|
Dec 17, 2021
| ILiAD Biotechnologies Announces First School-Age Participants Enrolled in BPZE1 Pertussis Vaccine Phase 2b SUPER Clinical Trial
|
Sep 29, 2021
| ILiAD Biotechnologies Reports Preliminary Data Demonstrating Pertussis Vaccine Candidate BPZE1, but Not Boostrix, Induces Functional Bactericidal Antibodies Against Pertactin Negative B. Pertussis
|
Oct 21, 2020
| ILiAD Biotechnologies Announces Upcoming Presentation at the European Society for Paediatric Infectious Diseases 2020 Virtual Meeting
|
Sep 29, 2020
| ILiAD Biotechnologies Reports Positive Topline Results from Phase 2b Trial for Pertussis Vaccine Candidate BPZE1
|
Sep 24, 2020
| ILiAD Biotechnologies Announces Presentation of Positive Phase 2b Data for Next Generation Pertussis Vaccine at World Vaccine Congress
|
Nov 19, 2019
| Dr. Cheryl Keech Joins ILiAD Biotechnologies as Chief Medical Officer and Executive VP of Clinical Research
|
Oct 8, 2019
| ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Full Enrollment In 300-Subject Multicenter Phase 2b Clinical Trial
|
Jun 25, 2019
| ILiAD Biotechnologies Announces First Patient Enrolled in BPZE1 Pertussis Vaccine Multicenter Phase 2b Clinical Trial
|
Dec 19, 2018
| ILiAD Biotechnologies Secures Up to $20 million of Financing and Phase 2a BPZE1 Pertussis Vaccine Trial Initiates at Vanderbilt University Medical Center
|
May 15, 2018
| NIAID Sponsors ILiAD Biotechnologies BPZE1 Pertussis Vaccine Phase 2a Clinical Study at Vanderbilt University
|
July 5, 2017
| ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones Including Positive Phase 1b Clinical Study Data
|
February 19, 2016
| Phase 1b Clinical Trial of BPZE1 Pertussis Vaccine Completes Enrollment of Randomized Study Groups
|
January 8, 2014
| ILiAD Biotechnologies, Inserm and Inserm Transfert SA, and Institut Pasteur de Lille Enter Scientific Collaboration and Worldwide License Agreements for Vaccine Technology
|
